Subasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid...
- Mechanism
- Curator reviewed · 2 references
Subasumstat binds and forms an adduct with SUMO, stopping the protein from transferring from the SUMO-activating enzyme to SUMO-conjugating enzyme UBC9. Downstream, this stops many sumoylated protein-mediated pathways from occurring in tumor cells, like DNA repair, metastasis, and proliferation. Subasumstat is also able to increase the production of type 1 interferon, which activates antitumor immune responses in cells and signals for increased tumor cell death.
- Formula / weight
- C25H28ClN5O5S2 · 578.1 g/mol (avg)
- Code names
- Sumoylation inhibitor TAK-981 · TAK-981
Resolves to
LXRZVMYMQHNYJB-UNXOBOICSA-NSMILESCC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2What you can answer from here — as of July 08, 2026
Which drugs share a target with Subasumstat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account